Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines
about
Molecular imaging: 18F-FDG PET and a whole lot more.Evaluation and comparison of human absorbed dose of (90)Y-DOTA-Cetuximab in various age groups based on distribution data in rats.Quantifying the cellular uptake of antibody-conjugated Au nanocages by two-photon microscopy and inductively coupled plasma mass spectrometry.Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of diseasePET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinomaComparison of conjugation strategies of cross-bridged macrocyclic chelators with cetuximab for copper-64 radiolabeling and PET imaging of EGFR in colorectal tumor-bearing mice.A novel PET imaging using ⁶⁴Cu-labeled monoclonal antibody against mesothelin commonly expressed on cancer cellsPET imaging of EGF receptors using [18F]FBEM-EGF in a head and neck squamous cell carcinoma model.Rift Valley fever virus strain MP-12 enters mammalian host cells via caveola-mediated endocytosis.Copper-64 Radiopharmaceuticals for Oncologic ImagingInterrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics.Preclinical evaluation of the anti-tumor effects of the natural isoflavone genistein in two xenograft mouse models monitored by [18F]FDG, [18F]FLT, and [64Cu]NODAGA-cetuximab small animal PET.Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET).EGFR-targeted Chimeras of Pseudomonas ToxA released into the extracellular milieu by attenuated Salmonella selectively kill tumor cells.Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: differences between antibodies and TK inhibitors.The role of p53 in combination radioimmunotherapy with 64Cu-DOTA-cetuximab and cisplatin in a mouse model of colorectal cancer.Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and TherapyMolecular imaging metrics to evaluate response to preclinical therapeutic regimens.Epidermal growth factor receptor as a biomarker for cervical cancer.Perspectives and potential applications of nanomedicine in breast and prostate cancer.Alternative PET tracers in head and neck cancer. A review.Imaging EGFR and HER2 by PET and SPECT: a review.99m Tc-anti-epidermal growth factor receptor nanobody for tumor imaging.PET of EGFR with (64) Cu-cetuximab-F(ab')2 in mice with head and neck squamous cell carcinoma xenografts.Flow cytometric cell-based assay to preselect antibody constructs for radionuclide conjugation.Cellular and molecular properties of (90)Y-labeled cetuximab in combination with radiotherapy on human tumor cells in vitro.Correlation between epidermal growth factor receptor-specific nanobody uptake and tumor burden: a tool for noninvasive monitoring of tumor response to therapy.Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with Cu-labeled trastuzumab PET.Quantifying the coverage density of poly(ethylene glycol) chains on the surface of gold nanostructures.Molecular Simulation of Receptor Occupancy and Tumor Penetration of an Antibody and Smaller Scaffolds: Application to Molecular Imaging.Novel PAMAM-PEG-Peptide Conjugates for siRNA Delivery Targeted to the Transferrin and Epidermal Growth Factor Receptors.Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model.Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography.Integrated treatment using intraperitoneal radioimmunotherapy and positron emission tomography-guided surgery with 64Cu-labeled cetuximab to treat early- and late-phase peritoneal dissemination in human gastrointestinal cancer xenografts.Benzofuran-appended 4-aminoquinazoline hybrids as epidermal growth factor receptor tyrosine kinase inhibitors: synthesis, biological evaluation and molecular docking studies
P2860
Q30482989-93511B41-3CB5-4066-B3C7-374D5939D947Q30584781-2B7971FF-45EE-436E-BDCD-8E64EC8E2310Q33517049-A719E2B2-A4D1-4058-8628-1B2504016AE9Q33870879-2284089F-E4A2-49CA-AD0E-D9D6257BE26CQ33939881-677385E9-8821-4844-9DAF-98CA657DF158Q33943630-15E73560-7601-42AE-BE9F-0A2BD8D28F6EQ34473719-C89309F6-EA41-4982-B174-F26686DAD38AQ35323396-B6E84AB6-5C30-4FF6-8110-3892F4DD397DQ35683116-607FC3EF-F491-4874-98F3-B8E6C81AD563Q36397378-E39DACA0-0D19-4C0F-B3E9-662356282EF8Q37126530-E0E28E56-474E-4819-B4FF-BAE163E0921DQ37236103-BAEC53BE-6CA1-4F08-A549-B31B72233A95Q37317527-1B8DE8D8-C3A0-4038-9313-32225621364AQ37356557-5C8AABE6-8383-468E-B426-C92E63DC8596Q37372414-396AFFF9-F783-4C42-9EC2-8E162BF6461FQ37628728-09EA90AA-FA4E-4251-81BF-0CB3A3E26313Q37639112-E683E794-13C5-47B7-A778-E9FA9252FA2DQ37689802-584101A6-6766-42E0-A804-418FD1B24977Q37825149-E2B8E315-F092-464E-9E68-63A32B0A60D1Q37843137-52797561-61A8-4B95-9C30-F626B98D7A18Q38067306-55101C6F-B28D-4B14-A9B8-96486A4D6C48Q38069937-F4FA106F-662A-4CAF-9C2E-EEAA99979DB4Q38137829-775DE0D4-43F0-46F5-B75F-403570CA7907Q38744686-E484F333-6FBB-4B2D-B79F-4CCE356C96B8Q38846349-15D2B966-9BBB-4971-9281-191EF7414417Q39289085-4CD4CCB0-D189-465B-9909-A32C46238375Q39300555-01C1E802-7DA8-47E6-BFC7-0D9A53190D61Q39652063-292878B0-BDDC-4EDB-B956-0EC59D191686Q39729571-E60EC9B1-CA5E-4850-B329-4C237819FBF4Q40640731-91463DD1-1CB0-48A4-8247-4DA0DD458EB7Q47967175-BCBF259D-77EF-4F47-9D55-E06A3BB8BD32Q48284313-CD0AEDED-28C4-4ABB-8D90-F5733E745309Q53265601-2C822215-7CC4-4A96-B4B9-D4B40C3083FDQ54336425-F578FFEA-DA29-4E13-9325-2A017D7F01C8Q55508871-77C99204-B40F-492A-8501-3100942D682AQ57023556-3728132C-8EEA-4BAB-9E77-DA6D6A676873
P2860
Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines
description
2008 nî lūn-bûn
@nan
2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Correlating EGFR expression wi ...... n 5 cervical cancer cell lines
@ast
Correlating EGFR expression wi ...... n 5 cervical cancer cell lines
@en
Correlating EGFR expression wi ...... n 5 cervical cancer cell lines
@nl
type
label
Correlating EGFR expression wi ...... n 5 cervical cancer cell lines
@ast
Correlating EGFR expression wi ...... n 5 cervical cancer cell lines
@en
Correlating EGFR expression wi ...... n 5 cervical cancer cell lines
@nl
prefLabel
Correlating EGFR expression wi ...... n 5 cervical cancer cell lines
@ast
Correlating EGFR expression wi ...... n 5 cervical cancer cell lines
@en
Correlating EGFR expression wi ...... n 5 cervical cancer cell lines
@nl
P2093
P2860
P1476
Correlating EGFR expression wi ...... n 5 cervical cancer cell lines
@en
P2093
Laura A Meyer
Linda J Pike
Mark A Watson
Martin Eiblmaier
Paula M Fracasso
P2860
P304
P356
10.2967/JNUMED.108.052316
P407
P577
2008-08-14T00:00:00Z